BMP2K and cancer: The higher rate of laNK92 stimulation with BiKE:E5C1 explains the observed higher rate of ADCC in cancer cells, which were treated with laNK92 plus BiKE:E5C1 compared to those treated with laNK92 plus trastuzumab.